Loading
cross-sectional MRI and EEG assessments (NO INTERVENTION) / Depression / Major Depressive Disorder · Observational Study
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed observational neuroimaging study designed to map reward-processing circuits (EEG and fMRI measures) across depressed individuals to identify neural subtypes; no results are posted in this registry record. The work is exploratory and mechanistic, intended to discover biomarkers that distinguish depressive phenotypes, but clinical utility and reproducibility remain unknown pending publication.
Observational. Depression, Depressive Disorder, Major Depressive Disorder, Major Depressive Episode, Depressive Symptoms, Anhedonia; age from 18 Years; to 70 Years; accepts healthy volunteers. Intervention: MDD (Major Depressive Disorder) Group; Unaffected Comparison Group. n = 158. 1 site: United States.
This is a completed observational neuroimaging study designed to map reward-processing circuits (EEG and fMRI measures) across depressed individuals to identify neural subtypes; no results are posted in this registry record. The work is exploratory and mechanistic, intended to discover biomarkers that distinguish depressive phenotypes, but clinical utility and reproducibility remain unknown pending publication.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No results are posted. Clinicians should await publication of outcome data to determine whether identified neural phenotypes predict treatment response, prognosis, or inform clinical decision-making. This study is hypothesis-generating and intended to improve disease classification, not to validate existing interventions.
Observational cross-sectional neuroimaging study with no results posted; designed to identify neural biomarkers in depression but recruitment completion alone does not constitute evidence of efficacy or clinical utility.
As stated by the source record.
Quoted from the source exactly as published.
No results are posted. Clinicians should await publication of outcome data to determine whether identified neural phenotypes predict treatment response, prognosis, or inform clinical decision-making. This study is hypothesis-generating and intended to improve disease classification, not to validate existing interventions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06080646). This is a study registration, not published results. Lead sponsor: San Francisco Veterans Affairs Medical Center. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 158 participants (ACTUAL). Conditions: Depression, Depressive Disorder, Major Depressive Disorder, Major Depressive Episode, Depressive Symptoms, Anhedonia. Interventions: OTHER: cross-sectional MRI and EEG assessments (NO INTERVENTION). Primary outcome measures: Stimulus preceding negativity , 1 month (EEG measure of reward anticipation); Reward positivity , 1 month (EEG measure of reward feedback); Late positive potential , 1 month (EEG measure of effective salience); fMRI response to win vs. loss reward feedback , 1 month (fMRI data). Brief summary: Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.